The metabolism of antipyrine (10 mg/kg i.v.) was studied in nine patients with cancer of the lung and in a cancer-free control group matched for age, sex, drug intake, and smoking and drinking history. The mean plasma clearance of antipyrine was 0.0475 ± 0.009 liter/kg/hr in the tumor group and 0.0557 ± 0.007 liter/kg/hr in the control group (p > 0.05). The antipyrine plasma elimination half-life was longer in the group with tumors (9.5 ± 1.3 hr) compared to the control group (7.7 ± 1.3 hr), but the difference was not statistically significant (p > 0.05). There was no difference between the groups in the excretion of two major antipyrine metabolites, 4-hydroxyantipyrine and N-demethylantipyrine, in a 48-hr urine sample. Thus, the presence of lung cancer in humans does not significantly alter antipyrine elimination.


Supported by Grants GM15956 from USPHS and Medical Research Service, Veterans Administration Hospital.

This content is only available via PDF.